Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinicMore about Open Access at the Crick
Authors listTimothy A Chan Mark Yarchoan Elizabeth Jaffee Charles Swanton Sergio A Quezada Albrecht Stenzinger Solange Peters
Treatment with immune checkpoint blockade (ICB) with agents such as anti-programmed cell death protein 1 (PD-1), anti-programmed death-ligand 1 (PD-L1), and/or anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) can result in impressive response rates and durable disease remission but only in a subset of patients with cancer. Expression of PD-L1 has demonstrated utility in selecting patients for response to ICB and has proven to be an important biomarker for patient selection. Tumor mutation burden (TMB) is emerging as a potential biomarker. However, refinement of interpretation and contextualization is required.
Journal Annals of Oncology
Issue number 1